NewLimit raises $435M as longevity biotech gets another big VC signal
NewLimit reportedly raised $435M, showing continued investor appetite for longevity science and cellular reprogramming.
What happened
NewLimit reportedly raised $435M at a valuation of around $3.1B.
The company is working in longevity biotech, with a focus on cellular reprogramming — a science-heavy area that aims to understand and potentially reverse aspects of biological ageing.
Why it matters
Longevity biotech sits at the intersection of deep science, software-style venture ambition, and very long timelines.
That makes it risky, but also highly attractive to investors looking for categories that could reshape healthcare if the science works.
The signal
This round suggests longevity is no longer just a niche “moonshot” category. It is becoming one of the big-ticket areas where tech investors are willing to make serious science bets.